Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, BridgeBio Pharma (BBIO) has a market cap of $6.51 billion USD. According to our data, BridgeBio Pharma is ranked No.2170 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $6.51 B |
25.57%
|
| Dec 31, 2024 | $5.19 B |
-32.03%
|
| Dec 29, 2023 | $7.63 B |
429.79%
|
| Dec 30, 2022 | $1.44 B |
-54.32%
|
| Dec 31, 2021 | $3.15 B |
-76.54%
|
| Dec 31, 2020 | $13.44 B |
102.88%
|
| Dec 31, 2019 | $6.62 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 BioMarin Pharmaceutical
BMRN
|
$11.51 B |
-0.000 M
|
USA
|
 Alnylam Pharmaceuticals
ALNY
|
$29.89 B |
-0.001 M
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$128.67 B |
-0.003 M
|
USA
|
 Sarepta Therapeutics
SRPT
|
$5.28 B |
-0.000 M
|
USA
|
 Ultragenyx
RARE
|
$3.32 B |
0.000 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Moderna
MRNA
|
$10.14 B |
-0.001 M
|
USA
|
 Ionis Pharmaceuticals
IONS
|
$4.51 B |
0.000 M
|
USA
|
 CRISPR Therapeutics
CRSP
|
$3.34 B |
0.000 M
|
Switzerland
|
 Editas Medicine
EDIT
|
$0.11 B |
0.000 M
|
USA
|
 Intellia Therapeutics
NTLA
|
$0.76 B |
-0.000 M
|
USA
|
 bluebird bio
BLUE
|
$43.76 M |
0.000 M
|
USA
|
 Sangamo Therapeutics
SGMO
|
$0.17 B |
0.000 M
|
USA
|
| Market Cap | = | BBIO Stock Price | * | BBIO Shares Outstanding |
| = | $34.24 | * | 0.19 B | |
| = | $6.51 B |